| Literature DB >> 17567922 |
Dagmar S Lang1, Daniel Droemann, Holger Schultz, Detlev Branscheid, Christian Martin, Anne R Ressmeyer, Peter Zabel, Ekkehard Vollmer, Torsten Goldmann.
Abstract
BACKGROUND: Non-small cell lung cancer (NSCLC) causes most of cancer related deaths in humans and is characterized by poor prognosis regarding efficiency of chemotherapeutical treatment and long-term survival of the patients. The purpose of the present study was the development of a human ex vivo tissue culture model and the analysis of the effects of conventional chemotherapy, which then can serve as a tool to test new chemotherapeutical regimens in NSCLC.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17567922 PMCID: PMC1913052 DOI: 10.1186/1465-9921-8-43
Source DB: PubMed Journal: Respir Res ISSN: 1465-9921
Figure 1Percentages of dead cells in human NSCLC tissue specimens following 16 h culture period ex vivo. Viability was also assessed without cultivation (native tumor; NAT TU) to compare for culture effects. Data are expressed as mean percentage of dead cells + STD (standard deviation) (n = 6) with Triton X values as 100%.
Effects of short-term cultivation upon expression of Ki-67 antigen and of cleaved caspase-3 expression in human NSCLC specimens of both adenocarcinoma and squamous cell carcinoma type. Data are expressed as mean values of percentages ± SEM.
| 29.2 ± 3.3 | 18.7 ± 2.5 | N = 20 | |||
| 41.7 ± 4.1 | 27.4 ± 2.5 | N = 19 | |||
| 12.0 ± 2.9 | 11.1 ± 2.7 | 0.87 | N = 18 | ||
| 9.2 ± 4.3 ( | 8.6 ± 1.3 ( | N = 17 | |||
AC : adenocarcinomas ; SCC : squamous cell carcinomas
NAT TU: native tumour (without cultivation); RPMI: cultivated tissues in medium
Effects of chemotherapeutical treatment upon expression of Ki-67 and of Caspase-3 in four human breast cancer tissue specimens. Data are expressed as median values of percentages ± SEM of positively stained tumour cells.
| 15.0 ± 4.3 | 27.5 ± 7.8 | 0.770 | ||
| 15.0 ± 5.5 | 27.5 ± 7.8 | 0.663 | ||
| 25.0 ± 5.5 | 12.5 ± 3.1 | 0.772 | ||
| 20.0 ± 6.6 | 12.5 ± 3.1 | 0.559 | ||
RPMI: medium control tissues; VIN: vinorelbine; GEM: gemcitabine
Figure 2Caspase-3 induction determined by flow cytometry in human cancer cell lines in the absence (RPMI) or presence of carboplatin (CARB), vinorelbine (VIN) and gemcitabine (GEM), respectively. The cell lines were plated 24 h before addition of the single drug. Percentage of caspase-3 positive cells are shown as mean values + SEM (n = 4–5).
Figure 3A-D: Induction of cleaved caspase-3 as determined by IHC in CPC-N cells (small-cell lung cancer) in the absence (A) or presence of carboplatin (B), vinorelbine (C) and gemcitabine (D), respectively (all 400×).
Figure 4Transcription of caspase-3 in four different human NSCLC tissue specimens (n = 3 SCC; n = 1 AC) and one human SCLC (small-cell lung cancer) tissue sample in the absence (RPMI) or presence of carboplatin (CARB), vinorelbine (VIN) and gemcitabine (GEM), respectively. Signals of caspase-3 were normalized to the respective GAPDH signals and the resulting values of the untreated medium control tissues (RPMI) were set 100%. The data are shown for each individual specimen separately and are expressed as mean values ± SEM (n = 2). Lines were drawn through all data points derived from a single specimen to better reveal the individual trend of response.
Effects of chemotherapeutical treatment on expression of proliferation (Ki-67, BrdU) and of apoptosis (cleaved caspase-3) in human NSCLC tissue specimens. Data are expressed as mean values of percentages ± SEM of positively stained tumour cells.
| 9.8 ± 2.2 | 18.0 ± 2.6 | N = 19 | |||
| 10.9 ± 2.4 | 18.2 ± 2.4 | N = 21 | |||
| 11.4 ± 2.1 | 21.2 ± 2.1 | N = 17 | |||
| 19.1 ± 2.4 | 26.6 ± 2.4 | 0.065 | N = 19 | ||
| 18.1 ± 2.6 | 27.3 ± 2.4 | N = 20 | |||
| 21.2 ± 2.9 | 28.8 ± 2.5 | 0.07 | N = 17 | ||
| 0.9 ± 0.5 | 5.5 ± 1.7 | N = 19 | |||
| 0.2 ± 0.1 | 6.0 ± 1.9 | N = 15 | |||
| 1.0 ± 0.4 | 6.8 ± 2.3 | 0.063 | N = 12 | ||
| 1.4 ± 0.6 | 4.7 ± 1.4 | 0.084 | N = 9 | ||
| 0.8 ± 0.4 | 4.9 ± 1.7 | 0.079 | N = 7 | ||
| 1.3 ± 0.7 | 4.9 ± 1.7 | 0.063 | N = 7 | ||
| 19.0 ± 4.6 | 11.1 ± 2.5 | 0.47 | N = 19 | ||
| 22.0 ± 5.5 | 10.6 ± 2.4 | 0.163 | N = 20 | ||
| 20.8 ± 6.4 | 10.1 ± 2.9 | 0.559 | N = 16 | ||
| 13.7 ± 3.2 | 8.3 ± 1.2 | 0.483 | N = 19 | ||
| 15.1 ± 3.1 | 7.8 ± 1.1 | 0.24 | N = 18 | ||
| 17.5 ± 3.1 | 8.3 ± 1.4 | N = 15 | |||
AC: Adenocarcinomas; SCC: Squamous cell carcinomas
RPMI: medium control tissues; CARB: carbolatin; VIN: vinorelbine; GEM: gemcitabine